Read E.V.I.dently Today for current news about health policy and events, among other topics.
E.V.I.dently Today Blog
When it comes to designing accountable care models, the dramatically varied needs and preferences of patients with cancer can confound quality measurement, especially when compounded by increasingly targeted diagnostics and treatments, and higher-cost approaches to care.
The Food and Drug Administration (FDA) this week has released a series of draft guidance documents that clarify how and when different types of clinical and economic information may be communicated.
In the December issue of Employee Benefit News, NPC Vice President of Comparative Effectiveness Research Jennifer Graff, PharmD, outlines a framework for the consideration of treatment flexibility in benefit design.